Porosome Therapeutics Unveils Breakthrough Discoveries in Alzheimer’s Research
Wednesday, August 06, 2025
Porosome Therapeutics has announced major developments in its neurological treatment platform aimed at tackling the root causes of Alzheimer’s disease (AD).
The company’s innovative approach offers a potential shift in AD treatment by focusing on disease modification rather than managing symptoms.
The company's core method, described as "Reprogram, Restore, and Rescue," involves introducing healthy porosomes – tiny nanomachines responsible for secretion in neurons – into diseased brain cells. This process aims to repair secretory and metabolic dysfunctions typically seen in Alzheimer’s, targeting the disease at a cellular level.
Recent organoid-based studies, validated by the U.S. Food and Drug Administration (FDA), have shown promising results. In these studies, AD human brain organoids treated with Porosome Therapeutics’ main therapy exhibited a significant reduction in Alzheimer’s-related pathology within a short time. Notably, the therapy also led to a measurable decline in Tau protein levels, which are recognised by the FDA as a key biomarker of the disease.
The company’s platform has also introduced three therapeutic classes for Alzheimer’s:
- Small Molecules and Peptides: Designed to cross the blood-brain barrier and restore mitochondrial function.
- Biologics: Aim to rebuild the porosome complex to correct neuronal secretory problems.
- AI-Designed Peptides: Artificial intelligence is being used to create specialised decoy peptides that neutralise the harmful beta amyloid (1-42) peptides, protecting essential brain functions.
These developments were demonstrated using human brain organoids – 3D cell cultures that replicate human brain structures and functions. In these models, the company reported noticeable improvements in just two weeks, reflecting the potential speed and effectiveness of the treatment.
In addition to cell restoration, Porosome Therapeutics is using AI tools to design peptides that bind more effectively to toxic beta amyloid (1-42), which is known to disrupt communication between neurons. By diverting these peptides away from critical cellular sites, the company aims to maintain healthy brain function.
Porosome Therapeutics has broadened its pipeline to include these novel therapeutic classes, marking a step forward in efforts to develop more effective treatments for Alzheimer’s disease.
Source: businesswire.com
